Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pediatrix Medical (MD) EBIT (2016 - 2025)

Pediatrix Medical (MD) has disclosed EBIT for 17 consecutive years, with -$114.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 391.59% to -$114.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.5 million, a 166.15% increase, with the full-year FY2025 number at $45.5 million, up 166.15% from a year prior.
  • EBIT was -$114.6 million for Q4 2025 at Pediatrix Medical, down from $68.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $68.1 million in Q3 2025 to a low of -$157.7 million in Q2 2024.
  • A 5-year average of $18.0 million and a median of $39.2 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 187.37% in 2021, then tumbled 425.22% in 2024.
  • Pediatrix Medical's EBIT stood at $68.0 million in 2021, then tumbled by 47.01% to $36.0 million in 2022, then crashed by 409.37% to -$111.5 million in 2023, then surged by 135.24% to $39.3 million in 2024, then tumbled by 391.59% to -$114.6 million in 2025.
  • Per Business Quant, the three most recent readings for MD's EBIT are -$114.6 million (Q4 2025), $68.1 million (Q3 2025), and $59.9 million (Q2 2025).